#brainMets
#MedSky #OncSky

NEW & IMPORTANT Genomic profiling performed on 822 #breastcancer #brainmets (BCBM) + thousands of local breast tumors & non-brain mets (unpaired).

🔑 HRD & #ImmunoOnc-predictive biomarkers are significantly more common in BCBM.

🔑 There were some diffs by #bcsm subtype.

/1
December 23, 2024 at 9:42 PM
Really excited to share our lab's first manuscript! I cant be more proud of our team, especially @nora-mae.bsky.social who diligently worked on this project.
It will be a long thread but I promise it's worth it!
#Oncology #BrainMets
February 28, 2025 at 2:27 PM
For Emma, losing her licence after a #LungCancer diagnosis with #BrainMets felt like losing her independence.

70% of #ALK+ pts get 🧠 mets, yet many don't get clear guidance on driving.

That’s why our DVLA Advisory Panel created this @pifonline.bsky.social certified guide #LCSM

📌 shorturl.at/k20oo
January 22, 2025 at 11:58 AM
Ther Adv Med Oncol: Real‑world pyrotinib beyond progression vs rechallenge in HER2+ mBC (incl. brain mets): PFS2 ~7.2 vs 6.3 mo (NS); OS 31.6 vs 21.0 mo (trend). CNS subgroup also benefited. Read: 【🔗https://buff.ly/xsK4lFw 】 #BreastCancer #HER2 #BrainMets #Oncology
March 7, 2026 at 8:15 AM
…or develop ways to deliver non-CNS-penetrant drugs to the central nervous system.

🔑 #OncSky #MedSky
We MUST include people w/ #brainmets, & as appropriate active untreated brain mets, in #Oncology #clinicaltrials. Preventing/treating CNS mets will be the final frontier in #bcsm.

/END
December 23, 2024 at 9:56 PM
Thrilled to be part of the upcoming Brain & Spine Metastases Conference! Join me and colleagues to explore the latest in brain and spine mets. Use code Ahmed for a discounted rate! Register here: www.gotoper.com/brainspinemets #BMC25 #BrainMets #SpineMets
CME / CE - Physicians' Education Resource
Physicians' Education Resource - Newest Continuing Medical Education Live Events, Webcasts & Online Activities
www.gotoper.com
January 8, 2026 at 2:42 AM
.@drsgraff.bsky.social provides a clear overview of treatments for HER2+ MBC with a lot of discussion around those living with #brainmets. ADCs are now indicated for patients with active CNS disease #OncoAlertColloquium #BreastCancer
February 5, 2025 at 5:50 PM
Fine-tune your strategies for using #HER2 targeting tx in HER2+ #MBC with and without #BrainMets: Get expert insight in this video from @PeerView & @graspcancer.bsky.social featuring Sara A. Hurvitz, MD, FACP, and colleagues. bit.ly/4fk0wD5
MDADI
MDADI
bit.ly
March 17, 2025 at 11:37 PM
Happening now! Join us to learn from this great group of speakers. #CNS #pediatricbraintumor #braintumor #glioma #gbm #neurosurgery #brainmets #brainmetastasis
April 11, 2025 at 12:45 PM
How can we improve care for people living with brain metastases?

Explore diagnosis, treatment decisions and support beyond treatment at our Brain Metastases Study Day.

5 November 2026 | Hybrid

Learn more: bit.ly/brainmetblue...

#brainmets #nhs #cancereducation
Brain Metastases Study Day | The Christie NHS Foundation Trust
This Christie School of Oncology study day is for healthcare professionals of any discipline on the management of brain metastases. Find out more today.
bit.ly
September 21, 2026 at 9:14 AM
💡 Clinical Tip: In MBC (esp. HER2+ & TNBC), discuss brain metastasis risk proactively — patient-centered dialogue is key while awaiting trial evidence.
#BreastCancer #BrainMets #MetastaticBC #OncoTwitter #MedicalWatch
August 26, 2025 at 2:44 PM
#OncSky #bcsm

👉Remember this, esp in isolated #brainmets or isolated CNS progression
👉Determine if we can reliably detect same alterations in CSF (or innovate to make 🧠 biopsy ⬇️ invasive)
👉Prioritize CNS penetrant agents w/ 👌 safety for #drugdevelopment

/3

www.nature.com/articles/s41...
Breast cancer brain metastases genomic profiling identifies alterations targetable by immune-checkpoint and PARP inhibitors - npj Precision Oncology
npj Precision Oncology - Breast cancer brain metastases genomic profiling identifies alterations targetable by immune-checkpoint and PARP inhibitors
www.nature.com
December 23, 2024 at 9:54 PM
👉 Recently published in Clinical Cancer Research: A population-level real-world analysis and single-center validation of melanoma brain metastasis epidemiology following dual-agent immunotherapy 🔗 doi.org/10.1158/1078... #EANOessentials #NeuroOncology #BrainMetastases #brainMets #medsky
July 11, 2025 at 8:18 AM
Hello! Formally introducing CIMARa. Led by CareyAnders
(@dukemets.bsky.social) and @HTawbi_MD
(@mdanderson.bsky.social), we are physicians, scientists, non-profits & advocates who share the goal of improving outcomes for patients with #brainmets through awareness & coordination of research.
June 6, 2025 at 1:57 PM
Analysis of 346 BCBM cases from the GEICAM RegistEM registry reveals faster CNS progression and poorer survival in TNBC and HER2+ subtypes, with major differences between de novo vs subsequent brain metastases.
🔗 buff.ly/74yHwuH
#BreastCancer #BrainMets #HER2 #TNBC #RealWorldEvidence
February 28, 2026 at 8:15 AM
Why are our findings significant?

Routine ERBB2 testing in EAC patients could guide early HER2-targeted therapy - and can identify high-risk patients for brain metastasis.

JAK2 alterations may help stratify patients for immunotherapy.

Thanks for reading!

#brainmets #oncology
February 28, 2025 at 2:27 PM
I cannot send enough ❤️ to EVERYONE involved with HER2CLIMB, for so many reasons but especially for the courage to include those w/ active #brainmets. #ASCO20 #bcsm @OncoAlert
November 18, 2024 at 8:25 AM
Dr. Veronica Chiang shares updates on three #clinicaltrials she is leading that target brain metastases. #brainmets
medicine.yale.edu/news-article...
Clinical Trials Target Brain Metastases
Veronica Chiang, MD, professor of neurosurgery, is currently leading several clinical trials seeking to improve treatments for brain metastases, or cancers that
medicine.yale.edu
January 16, 2026 at 3:01 PM
Even though she’s on the other coast, @SpiveySandra is asking great ?s of our panelists at #2019MetCancerEngagement, including one about how can imaging better distinguish between scar tissue from treatment and persistent #brainmets. Answer: imaging is getting there, stay tuned
November 18, 2024 at 5:03 PM
Yay @lianne_kraemer for asking why #DESTINY excluded patients with active #brainmets. This was a lost opportunity to potentially benefit people, as #HER2Climb showed! #SABCS19 #oncoalert #bcsm #StopExcludingBrainMets!
November 18, 2024 at 11:09 AM
Well, those of you that know me know that I was NOT going to get passed over to make a comment again. Challenging investigators to include people with untreated/active #brainmets in trials, even if initially as a very small cohort - thanks Dr Lin!! #SABCS19 #oncoalert #bcsm
November 18, 2024 at 11:09 AM
Study done in South and Central America. Oral drugs (if not prohibitively $$$) would be a boon in the developing world (and everywhere, because we’d all rather take a pill) Frustrating to us patients is that those with #brainmets were excluded #SABCS19 #oncoert #bcsm
November 18, 2024 at 10:48 AM
For #HER2 especially with #brainmets the HUGE news is #HER2climb using @SeattleGenetics Tucatinib. Huge because the trial included untreated/active brain mets and these patients had amazing results. 1/2 #SABCS19 #oncoalert #bcsm
November 18, 2024 at 10:48 AM